Inotiv, Inc. to Participate in September Investor Conferences
Inotiv, a prominent contract research organization, announced that Robert Leasure Jr. and Beth Taylor will attend two investor conferences in September 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inotiv, a prominent contract research organization, announced that Robert Leasure Jr. and Beth Taylor will attend two investor conferences in September 2022. The conferences include the 2022 Wells Fargo Healthcare Conference in Boston from September 7-9 and the Lake Street Capital Markets 6th Annual Best Ideas Growth Conference in New York City on September 14, 2022. Inotiv focuses on nonclinical and analytical drug discovery, aiming to enhance efficiency and reduce costs in drug development.
Details
News Market Reaction – NOTV
The recorded move for NOTV in the trading session of this news was +0.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST LAFAYETTE, Ind., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences during the month of September:
- 2022 Wells Fargo Healthcare Conference
Boston, MA / September 7-9
One-on-one meetings
- Lake Street Capital Markets 6th Annual Best Ideas Growth Conference
New York City / September 14, 2022
One-on-one meetings
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations |
| Inotiv, Inc. | The Equity Group Inc. |
| Beth A. Taylor, Chief Financial Officer | Devin Sullivan |
| (765) 497-8381 | (212) 836-9608 |
| btaylor@inotivco.com | dsullivan@equityny.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.